Disease Education Resources
Oncology
Explore our library of Lilly-created medical education resources. Please note: These resources do not offer CME/CE credit.
Breast Cancer - Early
Dr. Rugo: Identification and Treatment of Patients with HR+, HER2- EBC at a High Risk of Recurrence
Watch Dr. Rugo as she shares vital insights on identifying and managing patients with HR+, HER2- early breast cancer at high risk of recurrence. Learn about unmet needs, high-risk features, and treatment options to help individualize patient care.
Expert Insights on Early Identification to Reduce Recurrence Risk in HR+, HER2– EBC
Dr. Dawood and Prof. Johnston discuss the importance of identifying all high risk patients early, including those with lower nodal burden who remain at risk of recurrence.
HR+, HER2- Early Breast Cancer: Patient Case
An interactive case study for healthcare providers focused on identifying patients with HR+, HER2- EBC at high risk of recurrence.
Prof Johnston: Achieving Overall Survival in Adjuvant EBC
Expert insights into the historical barriers to demonstrating OS benefit with adjuvant endocrine therapy and the significance of progress.
Prof Johnston: CDK4/6 Inhibitor Efficacy and Safety Results in High-Risk HR+, HER2- EBC
Professor Stephen Johnston reviews CDK4/6 inhibitor clinical trial data in high-risk HR+, HER2- early breast cancer.
Supporting Adherence to Adjuvant Therapy in HR+, HER2– EBC
Expert discussion on using dose reduction and modification strategies to manage adverse events and support adherence to adjuvant therapy.
Explore the role of CDK4/6 inhibitors + endocrine therapy in high-risk HR+, HER2- early breast cancer. This deck addresses unmet needs, supporting data, and strategies to reduce recurrence risk, empowering evidence-based decisions for your patients.
Key clinical and pathological factors that help identify patients with HR+, HER2– early breast cancer at high risk of recurrence.
An overview of adjuvant CDK4/6 inhibitor use, trial design, and key efficacy endpoints in high risk HR+, HER2– early breast cancer trials.
An overview of adverse events and dose modification strategies to help patients with high risk HR+, HER2– early breast cancer stay on therapy.
Patient Education Resources
Explore our library of patient based education materials to aid in HCP to patient interactions.